Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC

Name: Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC
Uploaded: 2018-11-03T01:12:00.000Z
Description: Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.

November 2, 2018

Ravi Salgia, MD, PhD

Video

In Partnership With:

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non—small cell lung cancer (NSCLC).